BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 23126536)

  • 21. Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells.
    Zhang Y; Ma B; Zhou Y; Zhang M; Qiu X; Sui Y; Zhang X; Ma B; Fan Q
    Breast Cancer Res Treat; 2007 Nov; 105(3):277-86. PubMed ID: 17187233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Late dendritic cells are still able to evoke a potent alloreactive CTL response.
    Repnik U; Bergant M; Wraber B; Jeras M
    Immunobiology; 2008; 213(1):51-64. PubMed ID: 18207027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro.
    Delirezh N; Moazzeni SM; Shokri F; Shokrgozar MA; Atri M; Kokhaei P
    Cell Immunol; 2009; 257(1-2):23-31. PubMed ID: 19306994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concurrent delivery of tumor antigens and activation signals to dendritic cells by irradiated CD40 ligand-transfected tumor cells resulted in efficient activation of specific CD8+ T cells.
    Liu KJ; Lu LF; Cheng HT; Hung YM; Shiou SR; Whang-Peng J; Juang SH
    Cancer Gene Ther; 2004 Feb; 11(2):135-47. PubMed ID: 14647233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
    Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
    Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of cytolytic T lymphocytes against pediatric solid tumors in vitro using autologous dendritic cells pulsed with necrotic primary tumor.
    Shilyansky J; Jacobs P; Doffek K; Sugg SL
    J Pediatr Surg; 2007 Jan; 42(1):54-61; discussion 61. PubMed ID: 17208541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide.
    Nakahara S; Tsunoda T; Baba T; Asabe S; Tahara H
    Cancer Res; 2003 Jul; 63(14):4112-8. PubMed ID: 12874015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of leukemic-cell-specific cytotoxic T lymphocytes by autologous monocyte-derived dendritic cells presenting leukemic cell antigens.
    Lee JJ; Park MS; Park JS; Kang HK; Kim SK; Nguyen Pham TN; Zhu XW; Cho D; Nam JH; Kim YJ; Rhee JH; Chung IJ; Kim HJ
    J Clin Apher; 2006 Oct; 21(3):188-94. PubMed ID: 16570260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
    Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
    Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dendritic cells induce specific cytotoxic T lymphocytes against prostate cancer TRAMP-C2 cells loaded with freeze- thaw antigen and PEP-3 peptide.
    Liu XQ; Jiang R; Li SQ; Wang J; Yi FP
    Asian Pac J Cancer Prev; 2015; 16(2):571-8. PubMed ID: 25684489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
    Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
    Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals.
    Forsberg O; Carlsson B; Malmström PU; Ullenhag G; Tötterman TH; Essand M
    Prostate; 2009 Jan; 69(1):70-81. PubMed ID: 18814178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia.
    Lee JJ; Foon KA; Mailliard RB; Muthuswamy R; Kalinski P
    J Leukoc Biol; 2008 Jul; 84(1):319-25. PubMed ID: 18426971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dendritic cells engineered to secrete anti-DcR3 antibody augment cytotoxic T lymphocyte response against pancreatic cancer
    Chen J; Guo XZ; Li HY; Zhao JJ; Xu WD
    World J Gastroenterol; 2017 Feb; 23(5):817-829. PubMed ID: 28223726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
    Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of specific human cytotoxic T cells using dendritic cells transduced with an adenovector encoding rat epidermal growth factor receptor 2.
    Suresh K; Scheid E; Klotz L; Venkateswaran V; Gauldie J; Foley R
    Int J Oncol; 2011 Oct; 39(4):907-13. PubMed ID: 21769423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumour-loaded α-type 1-polarized dendritic cells from patients with chronic lymphocytic leukaemia produce a superior NK-, NKT- and CD8+ T cell-attracting chemokine profile.
    Gustafsson K; Junevik K; Werlenius O; Holmgren S; Karlsson-Parra A; Andersson PO
    Scand J Immunol; 2011 Sep; 74(3):318-326. PubMed ID: 21595737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ex vivo host response to gastrointestinal cancer cells presented by autologous dendritic cells.
    Galetto A; Contarini M; Sapino A; Cassoni P; Consalvo E; Forno S; Pezzi C; Barnaba V; Mussa A; Matera L
    J Surg Res; 2001 Sep; 100(1):32-8. PubMed ID: 11516202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.